Moderna (MRNA) Return on Sales (2017 - 2025)
Historic Return on Sales for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to 0.2%.
- Moderna's Return on Sales fell 2000.0% to 0.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.4%, marking a year-over-year decrease of 9500.0%. This contributed to the annual value of 1.1% for FY2024, which is 4100.0% down from last year.
- Latest data reveals that Moderna reported Return on Sales of 0.2% as of Q3 2025, which was down 2000.0% from 5.81% recorded in Q2 2025.
- In the past 5 years, Moderna's Return on Sales ranged from a high of 0.68% in Q4 2021 and a low of 8.99% during Q1 2025
- For the 5-year period, Moderna's Return on Sales averaged around 1.69%, with its median value being 0.04% (2023).
- Per our database at Business Quant, Moderna's Return on Sales skyrocketed by 161300bps in 2021 and then crashed by -70800bps in 2024.
- Quarter analysis of 5 years shows Moderna's Return on Sales stood at 0.68% in 2021, then tumbled by -57bps to 0.29% in 2022, then crashed by -73bps to 0.08% in 2023, then crashed by -1602bps to 1.16% in 2024, then skyrocketed by 83bps to 0.2% in 2025.
- Its Return on Sales stands at 0.2% for Q3 2025, versus 5.81% for Q2 2025 and 8.99% for Q1 2025.